GLMD:NSC-Galmed Pharmaceuticals Ltd.

EQUITY | Biotechnology | NASDAQ Capital Market

Last Closing Price

USD 11.95

Change

+0.60 (+5.29)%

Market Cap

USD 0.25B

Volume

0.19M

Average Target Price

USD 14.00 (17.15%)
Average Analyst Rating

Verdict

STA Verdict

Verdict

About

Galmed Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company. It is engaged in the development and commercialization of oral therapy for the treatment of liver diseases and cholesterol gallstones.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2018-10-16 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
AMGN Amgen Inc.

+6.75 (+3.45%)

USD 130.97B
GILD Gilead Sciences Inc.

+3.53 (+4.85%)

USD 98.92B
BIIB Biogen Inc.

+10.20 (+3.11%)

USD 68.21B
CELG Celgene Corporation

+2.45 (+2.99%)

USD 59.28B
SHPG Shire plc

+3.34 (+1.94%)

USD 53.51B
VRTX Vertex Pharmaceuticals Incorpo..

+7.80 (+4.39%)

USD 47.39B
REGN Regeneron Pharmaceuticals Inc.

+20.97 (+5.55%)

USD 43.06B
ALXN Alexion Pharmaceuticals Inc.

+6.21 (+5.11%)

USD 28.46B
BMRN BioMarin Pharmaceutical Inc.

+6.56 (+6.60%)

USD 18.83B
INCY Incyte Corporation

+2.88 (+4.64%)

USD 13.80B

ETFs Containing GLMD

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange (NASDAQ Capital Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 30.60% 77% C+ 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 30.60% 76% C 84% B
Trailing 12 Months  
Capital Gain 36.42% 79% C+ 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 36.42% 79% C+ 84% B
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 19.33% 64% D 75% C
Dividend Return 19.33% 64% D 73% C
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 59.44% 38% F 15% F
Risk Adjusted Return 32.52% 66% D 45% F
Market Capitalization 0.04B 47% F 43% F

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
(NASDAQ Capital Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -14.23 85% B 84% B
Price/Book Ratio 13.90 10% F 7% F
Price / Cash Flow Ratio -3.69 79% C+ 88% B+
Price/Free Cash Flow Ratio -16.83 79% C+ 84% B
Management Effectiveness  
Return on Equity -36.66% 65% D 23% F
Return on Invested Capital -36.96% 67% D+ 23% F
Return on Assets -33.14% 67% D+ 20% F
Debt to Equity Ratio N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

GLMD:NSC-Galmed Pharmaceuticals Ltd.

EQUITY | Biotechnology | NASDAQ Capital Market

Last Closing Price

USD 11.95

Change

+0.60 (+5.29)%

Market Cap

USD 0.25B

Volume

0.19M

Average Target Price

USD 14.00 (17.15%)
Average Analyst Rating

Verdict

STA Verdict

Verdict

Values as of: 2018-10-16